iOmx Therapeutics Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
56
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$76.3M
- Investors
-
7
iOmx Therapeutics General Information
Description
Developer of cancer therapeutics designed to address the immune checkpoint modulators on tumor cells. The company's therapeutics focuses on systematically screening human tumor cells, breaking down the inherent resistance mechanisms of tumors against immune attack often mediated by cell surface molecules that stimulate immune-inhibitory receptors on T cells, enabling healthcare institutions to offer cancer immune-checkpoint therapy.
Contact Information
Website
www.iomx.comCorporate Office
- Fraunhoferstrasse 22
- Martinsried
- 82152 Munich
- Germany
Corporate Office
- Fraunhoferstrasse 22
- Martinsried
- 82152 Munich
- Germany
iOmx Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series B) | 05-Oct-2021 | $76.3M | Completed | Clinical Trials - Phase 2 | ||
| 2. Early Stage VC (Series A) | 22-Sep-2016 | Completed | Clinical Trials - Phase 2 | |||
| 1. University Spin-Out | 26-Apr-2016 | Completed | Clinical Trials - Phase 2 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
iOmx Therapeutics Comparisons
Industry
Financing
Details
iOmx Therapeutics Competitors (71)
One of iOmx Therapeutics’s 71 competitors is Aro Biotherapeutics, a Venture Capital-Backed company based in Philadelphia, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aro Biotherapeutics | Venture Capital-Backed | Philadelphia, PA | ||||
| Amal Therapeutics | Formerly VC-backed | Geneva, Switzerland | ||||
| Marengo Therapeutics | Venture Capital-Backed | Cambridge, MA | ||||
| Noveome Biotherapeutics | Venture Capital-Backed | Pittsburgh, PA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA |
iOmx Therapeutics Patents
iOmx Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026195655-A1 | Antibodies targeting c-c chemokine receptor type 9 (ccr9) protein, and uses thereof | Pending | 17-Mar-2025 | ||
| WO-2026003224-A2 | Bispecific antigen binding proteins (abp) targeting immune checkpoint molecules and both leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2; combinations and uses thereof | Pending | 26-Jun-2024 | ||
| WO-2026003224-A3 | Bispecific antigen binding proteins (abp) targeting immune checkpoint molecules and both leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2; combinations and uses thereof | Pending | 26-Jun-2024 | ||
| EP-4643861-B1 | A halogenated heteroaryl kinase inhibitor for use in treating angiosarcoma | Active | 30-Apr-2024 | ||
| EP-4643861-A1 | A halogenated-heteroaryl kinase inhbitor for treating soft tissue sarcoma and vascular tumors | Active | 30-Apr-2024 | A61P35/00 |
iOmx Therapeutics Signals
iOmx Therapeutics Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Athos Service | Family Office | Minority | ||
| MIG AG | Venture Capital | Minority | ||
| MPM BioImpact | Venture Capital | Minority | ||
| M Ventures | Corporate Venture Capital | Minority | ||
| Sofinnova Partners | Venture Capital | Minority |
iOmx Therapeutics FAQs
-
When was iOmx Therapeutics founded?
iOmx Therapeutics was founded in 2016.
-
Where is iOmx Therapeutics headquartered?
iOmx Therapeutics is headquartered in Munich, Germany.
-
What is the size of iOmx Therapeutics?
iOmx Therapeutics has 56 total employees.
-
What industry is iOmx Therapeutics in?
iOmx Therapeutics’s primary industry is Drug Discovery.
-
Is iOmx Therapeutics a private or public company?
iOmx Therapeutics is a Private company.
-
What is iOmx Therapeutics’s current revenue?
The current revenue for iOmx Therapeutics is .
-
How much funding has iOmx Therapeutics raised over time?
iOmx Therapeutics has raised $121M.
-
Who are iOmx Therapeutics’s investors?
Athos Service, MIG AG, MPM BioImpact, M Ventures, and Sofinnova Partners are 5 of 7 investors who have invested in iOmx Therapeutics.
-
Who are iOmx Therapeutics’s competitors?
Aro Biotherapeutics, Amal Therapeutics, Marengo Therapeutics, Noveome Biotherapeutics, and Kite Pharma are some of the 71 competitors of iOmx Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process